{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:19:27Z","timestamp":1790792367429,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.3816\/cbc.2010.n.039","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T22:51:50Z","timestamp":1282085510000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer"],"prefix":"10.3816","volume":"10","author":[{"given":"Raffaele","family":"Addeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sgambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Cennamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Montella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Faiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2010.n.039_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.2910460220","article-title":"Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules","volume":"46","author":"Binet","year":"1990","journal-title":"Int J Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Fitch M et al. Patient preference for oral vs. intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","article-title":"Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with with solid tumours","volume":"12","author":"Marty","year":"2001","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00228-002-0506-x","article-title":"A simultaneous oral\/intravenous population pharmacokinetics model forf vinorelbine","volume":"58","author":"Variol","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 2","key":"10.3816\/CBC.2010.n.039_bib5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2005.07.030","article-title":"Goals of treatment for patients with metastatic breast cancer","volume":"33","author":"Smith","year":"2006","journal-title":"Semin Oncol"},{"issue":"suppl 3","key":"10.3816\/CBC.2010.n.039_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.10-90003-1","article-title":"Optimizing first-line treatment options for patients with advanced NSCLC","volume":"10","author":"Wakelee","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.039_bib7","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1634\/theoncologist.10-3-198","article-title":"Never too old? Age should not be a barrier to enrollment in cancer clinical trials","volume":"10","author":"Aapro","year":"2005","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2010.n.039_bib8","first-page":"1355","article-title":"Treating advanced breast cancer in the older woman","volume":"20","author":"Extermann","year":"2006","journal-title":"Oncology"},{"key":"10.3816\/CBC.2010.n.039_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0959-8049(96)00426-1","article-title":"Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer","volume":"33","author":"Sorio","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1177\/107327480000700606","article-title":"Chemotherapy in the elderly: pharmacologic considerations","volume":"7","author":"Lichtman","year":"2000","journal-title":"Cancer Control"},{"key":"10.3816\/CBC.2010.n.039_bib11","first-page":"35","article-title":"Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy","volume":"21","author":"Freyer","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.3816\/CBC.2010.n.039_bib12","doi-asserted-by":"crossref","first-page":"s195","DOI":"10.1016\/S0959-8049(01)81205-3","article-title":"Efficacy and safety of oral navelbine in first line metastatic breast cancer (MBC)","volume":"37","author":"Amadori","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(01)00587-3","article-title":"Metronomic scheduling: the future of chemotherapy?","volume":"2","author":"Gasparini","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/14796694.3.2.183","article-title":"Antiangiogenic properties of metronomic chemotherapy in breast cancer","volume":"3","author":"Tonini","year":"2007","journal-title":"Future Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.3816\/CBC.2010.n.039_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CBC.2010.n.039_bib17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.3816\/CBC.2010.n.039_bib18","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1200\/JCO.1994.12.9.1754","article-title":"Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors","volume":"12","author":"Rowinsky","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1517\/14740338.4.5.915","article-title":"Oral versus intravenous vinorelbine: clinical safety profile","volume":"4","author":"Gebbia","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.3816\/CBC.2010.n.039_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdj130","article-title":"Phase II trial of vinorelbine for the treatment of metastatic breast cancer in patients >65 years of age: an NCCTG study","volume":"17","author":"Baweja","year":"2006","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2010.n.039_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2165\/00003495-200767050-00002","article-title":"Oral vinorelbine: role in the management of metastatic breast cancer","volume":"67","author":"Aapro","year":"2007","journal-title":"Drugs"},{"key":"10.3816\/CBC.2010.n.039_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3816\/CLC.2007.n.019","article-title":"A phase II study of single-agent oral vinorelbine in patients with pretreated advanced non\u2013small-cell lung cancer","volume":"8","author":"Rossi","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib24","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-05-3885","article-title":"Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells","volume":"66","author":"Pourroy","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2010.n.039_bib25","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2010.n.039_bib26","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood.V94.12.4143","article-title":"Antiangiogenesis is produced by nontoxic doses of vinblastine","volume":"94","author":"Vacca","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CBC.2010.n.039_bib27","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.ejca.2006.06.019","article-title":"Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development","volume":"42","author":"Krucynski","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2010.n.039_bib28","doi-asserted-by":"crossref","first-page":"7871","DOI":"10.1158\/1078-0432.CCR-08-0593","article-title":"VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy","volume":"14","author":"Burstein","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911700428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911700428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:19Z","timestamp":1761512719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911700428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1526820911700428"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2010.n.039","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2010.n.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}